Please select the option that best describes you:
Topics:
Rheumatology • Rheumatoid Arthritis • Vasculitis • Rituximab • General Rheumatology • Infectious Disease • Pulmonology • General Pulmonary • General Infectious Disease • Oncology
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
Does your approach differ based on the underlying condition - such as ANCA-associated vasculitis, rheumatoid arthritis, or another autoimmune disease?
Answer from: at Community Practice
Risk for PJP infection is usually in the context of moderate-high dose corticosteroid therapy or low T cell counts.
Sign In or Register to read more
Answer from: at Academic Institution
Some experts suggest consideration of stopping PJP prophylaxis in lower risk patients once the steroid dosage is below prednisone 10-15mg daily (PMID 29459427). A patient still on Rituximab but on minimal/no steroids and with a normal lymphocyte/CD4 count would be at lower risk.You can assess for ly...